Gastroenterology & Hepatology — MCQs

A 36-year-old man presents with a 10-month history of abdominal bloating, increased flatulence, and loose stools occurring 4-5 times daily without blood or mucus. He has no weight loss. He underwent testing for coeliac disease 2 years ago which was negative. Examination is unremarkable. He tries a low-FODMAP diet for 6 weeks with minimal improvement. Blood tests including full blood count, CRP, and thyroid function are normal. What is the most appropriate next investigation?

Q34

A 58-year-old man is admitted with acute pancreatitis secondary to gallstones. His admission amylase is 2400 U/L. Initial CT shows pancreatic oedema without necrosis. He is managed conservatively with fluid resuscitation and analgesia. On day 10, he develops a fever of 38.5°C and persistent abdominal pain. Repeat CT shows a 6 cm well-defined peripancreatic fluid collection with no gas. Blood cultures are negative. CRP is 220 mg/L. What is the most appropriate next step in management?

Q35

Which of the following best describes the mechanism of action of 5-aminosalicylic acid (5-ASA) compounds in the treatment of ulcerative colitis?

Q36

A 45-year-old woman presents with acute onset severe epigastric pain radiating to the back, with nausea and vomiting. Her amylase is 1450 U/L (normal <100 U/L). CT abdomen shows pancreatic oedema and peripancreatic fluid but no necrosis. CRP is 180 mg/L. She admits to drinking half a bottle of wine daily. Calcium is 2.15 mmol/L, and arterial blood gas shows pH 7.38, pO2 11.2 kPa, pCO2 4.8 kPa. What is her predicted severity of acute pancreatitis according to the Glasgow score at 48 hours?

Q37

A 65-year-old man with alcoholic cirrhosis and refractory ascites undergoes transjugular intrahepatic portosystemic shunt (TIPS) insertion. Before the procedure, his Model for End-Stage Liver Disease (MELD) score is 16, and his serum bilirubin is 42 μmol/L. Two weeks post-procedure, he develops progressive confusion and disorientation. His ascites has improved significantly. Liver function shows bilirubin 48 μmol/L, albumin 29 g/L, and INR 1.9. Ammonia level is elevated at 95 μmol/L (normal 11-35). What is the most likely complication?

Q38

A 29-year-old woman presents with a 2-year history of burning epigastric pain and acid regurgitation occurring 3-4 times per week, particularly at night. She has tried lifestyle modifications without improvement. BMI is 23 kg/m². Helicobacter pylori stool antigen test is negative. She is otherwise well and takes no regular medications. What is the most appropriate initial pharmacological management?

Q39

A 54-year-old man with alcoholic cirrhosis and large oesophageal varices on recent endoscopy is commenced on prophylactic carvedilol. After 4 weeks, his resting heart rate has decreased from 82 bpm to 58 bpm. He reports mild fatigue but no dizziness or syncope. Blood pressure is 108/68 mmHg. Liver function tests show bilirubin 38 μmol/L, albumin 32 g/L, and INR 1.6. What is the most appropriate management of his carvedilol therapy?

Q40

A 33-year-old man presents with a 4-week history of intermittent lower abdominal cramping and loose stools occurring 3-4 times daily. He reports that symptoms worsen with stress and improve after bowel movements. There is no blood in the stools, no nocturnal symptoms, and no weight loss. Examination is unremarkable. Blood tests including full blood count, inflammatory markers, coeliac serology, and thyroid function are all normal. Faecal calprotectin is 18 μg/g (normal <50 μg/g). What is the most appropriate next step?

Gastroenterology & Hepatology UK Medical PG Practice Questions and MCQs

Question 31: A 48-year-old woman presents with recurrent episodes of flushing, diarrhea, and wheezing. 24-hour urine 5-HIAA is markedly elevated. CT shows a small bowel mass with liver metastases. What is the most likely diagnosis?

A. Gastrinoma
B. Carcinoid tumor (Correct Answer)
C. Insulinoma
D. Glucagonoma
E. VIPoma

Explanation: ***Carcinoid tumor*** - Recurrent episodes of **flushing**, secretory **diarrhea**, and **wheezing** are classic features of **carcinoid syndrome**, caused by the release of vasoactive substances like **serotonin** from the tumor. - The diagnosis is confirmed by a markedly elevated **24-hour urine 5-HIAA** (5-hydroxyindoleacetic acid), the primary metabolite of **serotonin**. *Gastrinoma* - This tumor causes **Zollinger-Ellison syndrome**, characterized by severe, recurrent peptic ulcers and refractory GERD due to excessive **gastrin** secretion. - Diagnosis involves measuring fasting serum **gastrin levels** and a **secretin stimulation test**, not urine 5-HIAA. *Insulinoma* - Symptoms primarily revolve around **hypoglycemia**, forming **Whipple's triad** (symptoms with fasting, low glucose, relief with glucose). - It secretes excessive **insulin**, leading to neuroglycopenic symptoms, not the systemic effects seen in the patient. *Glucagonoma* - Characterized by **migratory necrolytic erythema**, often accompanied by **diabetes mellitus** and weight loss. - This condition involves the overproduction of **glucagon**, and the described symptoms of flushing, diarrhea, and wheezing are atypical. *VIPoma* - Presents with **WDHA syndrome** (**W**atery **D**iarrhea, **H**ypokalemia, **A**chlorhydria), which involves profound, high-volume secretory diarrhea. - The symptoms are due to excessive **Vasoactive Intestinal Peptide (VIP)** secretion and do not typically include flushing or wheezing.

Question 32: A 55-year-old man presents with progressive dysphagia and a 15kg weight loss over 4 months. He has a history of achalasia treated 10 years ago. Upper endoscopy shows a stricturing lesion at the gastroesophageal junction. What is the most likely diagnosis?

A. Recurrent achalasia
B. Esophageal adenocarcinoma (Correct Answer)
C. Benign stricture
D. Eosinophilic esophagitis
E. Candida esophagitis

Explanation: ***Esophageal adenocarcinoma***- The combination of **progressive dysphagia** and rapid **15kg weight loss** over 4 months is highly suggestive of advanced malignancy.- Long-standing **achalasia** is a significant predisposing factor for esophageal cancer (especially squamous cell carcinoma, but adenocarcinoma can occur at the GEJ), making malignancy the most likely diagnosis given the new stricturing lesion. *Recurrent achalasia*- Achalasia typically presents with non-progressive or intermittent dysphagia and regurgitation, but not the rapid, **severe weight loss** or a **stricturing lesion** indicative of malignancy.- Endoscopically, recurrent achalasia would show persistent dilatation with a smooth, non-infiltrative narrowing at the GEJ, not a distinct stricture. *Benign stricture*- While benign strictures cause dysphagia, they typically progress more slowly and do not cause such **severe and rapid weight loss** (15kg in 4 months).- Given the history of **achalasia**, a known premalignant condition, and the rapid progression, malignancy is a far more concerning and likely diagnosis than a benign stricture. *Eosinophilic esophagitis*- This condition typically causes intermittent dysphagia, often with **food impaction**, and is usually associated with symptoms of **atopy** (allergies, asthma).- It rarely causes rapid, profound **weight loss** or a dominant, stricturing lesion indicative of a tumor; endoscopic findings often include rings or furrows. *Candida esophagitis*- This infection usually causes **odynophagia** (painful swallowing) and is primarily seen in **immunocompromised** patients.- Endoscopically, it presents as white, adherent plaques and would not typically cause a firm, rapidly progressive, stricturing mass associated with severe weight loss.

Question 33: A 36-year-old man presents with a 10-month history of abdominal bloating, increased flatulence, and loose stools occurring 4-5 times daily without blood or mucus. He has no weight loss. He underwent testing for coeliac disease 2 years ago which was negative. Examination is unremarkable. He tries a low-FODMAP diet for 6 weeks with minimal improvement. Blood tests including full blood count, CRP, and thyroid function are normal. What is the most appropriate next investigation?

A. Hydrogen breath test for lactose intolerance
B. Repeat tissue transglutaminase antibody testing with total IgA level
C. Hydrogen and methane breath test after lactulose or glucose challenge (Correct Answer)
D. Colonoscopy with terminal ileal intubation and biopsies
E. SeHCAT scan to assess bile acid malabsorption

Explanation: ***Hydrogen and methane breath test after lactulose or glucose challenge*** - This patient presents with classic symptoms of **abdominal bloating**, **flatulence**, and **loose stools** that have not improved with a **low-FODMAP diet**, strongly suggesting **Small Intestinal Bacterial Overgrowth (SIBO)**. - A breath test using **lactulose or glucose** measures both **hydrogen and methane** gases produced by bacteria in the small intestine, providing a comprehensive assessment for SIBO. *Hydrogen breath test for lactose intolerance* - While lactose intolerance causes similar symptoms like bloating and diarrhea, this test specifically assesses **lactose malabsorption** rather than a generalized overgrowth of bacteria. - The patient's lack of improvement on a **low-FODMAP diet**, which already restricts lactose, makes isolated lactose intolerance less likely to be the primary cause. *Repeat tissue transglutaminase antibody testing with total IgA level* - The patient had negative **coeliac disease** testing two years ago, and his current symptoms developed more recently, making a repeat screen less urgent without other suggestive features. - Absence of **weight loss** and normal inflammatory markers further reduce the likelihood of active coeliac disease as the immediate concern. *Colonoscopy with terminal ileal intubation and biopsies* - This invasive investigation is typically reserved for patients with **alarm features** such as significant weight loss, rectal bleeding, or elevated inflammatory markers (e.g., **CRP**), none of which are present here. - Given the patient's normal blood tests and chronic non-bloody diarrhea, a functional or malabsorptive cause like SIBO is more probable than structural bowel disease. *SeHCAT scan to assess bile acid malabsorption* - **Bile acid malabsorption** can cause chronic diarrhea but is often considered after excluding more common causes or in patients with risk factors like **ileal resection** or cholecystectomy. - The prominent symptoms of **bloating** and **flatulence**, combined with the failure of the low-FODMAP diet, point more directly towards SIBO as the next diagnostic step.

Question 34: A 58-year-old man is admitted with acute pancreatitis secondary to gallstones. His admission amylase is 2400 U/L. Initial CT shows pancreatic oedema without necrosis. He is managed conservatively with fluid resuscitation and analgesia. On day 10, he develops a fever of 38.5°C and persistent abdominal pain. Repeat CT shows a 6 cm well-defined peripancreatic fluid collection with no gas. Blood cultures are negative. CRP is 220 mg/L. What is the most appropriate next step in management?

A. Arrange urgent percutaneous drainage of the collection
B. Continue conservative management as this represents an acute peripancreatic fluid collection (Correct Answer)
C. Arrange CT-guided fine needle aspiration for culture before starting antibiotics
D. Proceed to urgent surgical necrosectomy
E. Start empirical broad-spectrum antibiotics and repeat imaging in 2 weeks

Explanation: ***Continue conservative management as this represents an acute peripancreatic fluid collection*** - This presentation, with a well-defined peripancreatic fluid collection within **10 days** of acute pancreatitis onset and **no signs of necrosis or gas** (indicating infection), is consistent with an **Acute Peripancreatic Fluid Collection (APFC)** according to the Revised Atlanta Classification. - Most APFCs are **sterile** and **resolve spontaneously** without intervention; the fever and elevated CRP can reflect systemic inflammation from pancreatitis itself. *Arrange urgent percutaneous drainage of the collection* - **Percutaneous drainage** is generally reserved for **symptomatic pseudocysts** (mature collections >4 weeks) or **infected pancreatic necrosis**. - Early drainage of a sterile APFC is usually not indicated and can potentially introduce **infection** or create a **fistula**. *Arrange CT-guided fine needle aspiration for culture before starting antibiotics* - **CT-guided FNA** for culture is generally discouraged unless there is strong clinical suspicion of **infected necrosis** that is not responding to conservative management. - In the absence of clear signs of infection within the collection (no gas), and with negative blood cultures, the immediate need for FNA is not present. *Proceed to urgent surgical necrosectomy* - **Surgical necrosectomy** is indicated only for **infected pancreatic necrosis**, which is absent in this case (initial CT showed only oedema). - The current approach for severe pancreatitis favors **minimally invasive techniques** for walled-off necrosis, not urgent open surgery for an APFC. *Start empirical broad-spectrum antibiotics and repeat imaging in 2 weeks* - **Prophylactic antibiotics** are **not recommended** in acute pancreatitis, even in severe cases or with sterile fluid collections. - Antibiotics should only be initiated if there is evidence of **documented infection**, such as infected necrosis (with positive cultures or gas in the collection) or an extra-pancreatic infection.

Question 35: Which of the following best describes the mechanism of action of 5-aminosalicylic acid (5-ASA) compounds in the treatment of ulcerative colitis?

A. Inhibition of calcineurin leading to reduced T-cell activation
B. Inhibition of nuclear factor kappa B and inflammatory cytokine production (Correct Answer)
C. Blockade of alpha-4 integrin preventing leucocyte migration to gut tissue
D. Neutralization of tumour necrosis factor-alpha in the circulation
E. Inhibition of Janus kinase pathways reducing inflammatory signalling

Explanation: ***Inhibition of nuclear factor kappa B and inflammatory cytokine production***- **5-aminosalicylic acid (5-ASA)** compounds primarily act locally in the intestinal mucosa to inhibit the activation of **nuclear factor kappa B (NF-κB)**, a key transcription factor for inflammatory genes.- This inhibition reduces the production of various **pro-inflammatory cytokines** (e.g., TNF-α, IL-1, IL-6), as well as **prostaglandins** and **leukotrienes** by inhibiting cyclooxygenase and lipoxygenase pathways. *Inhibition of calcineurin leading to reduced T-cell activation*- This mechanism is characteristic of **calcineurin inhibitors** such as **cyclosporine** and **tacrolimus**, which are potent immunosuppressants.- These agents are typically reserved for severe, steroid-refractory cases of **ulcerative colitis**, and are not the primary mechanism of 5-ASA. *Blockade of alpha-4 integrin preventing leucocyte migration to gut tissue*- This describes the mechanism of **vedolizumab**, a gut-selective monoclonal antibody used in inflammatory bowel disease.- It specifically targets the **α4β7 integrin**, preventing leukocytes from migrating into the inflamed gastrointestinal tissue. *Neutralization of tumour necrosis factor-alpha in the circulation*- This is the mechanism of **anti-TNF agents** like **infliximab** or **adalimumab**, which are biologic therapies.- These drugs bind to and neutralize **tumour necrosis factor-alpha (TNF-α)**, a crucial pro-inflammatory cytokine in IBD. *Inhibition of Janus kinase pathways reducing inflammatory signalling*- This mechanism is associated with **Janus kinase (JAK) inhibitors** such as **tofacitinib** or **upadacitinib**.- These are small-molecule drugs that block intracellular signaling pathways downstream of many pro-inflammatory cytokine receptors, thereby reducing inflammation.

Question 36: A 45-year-old woman presents with acute onset severe epigastric pain radiating to the back, with nausea and vomiting. Her amylase is 1450 U/L (normal <100 U/L). CT abdomen shows pancreatic oedema and peripancreatic fluid but no necrosis. CRP is 180 mg/L. She admits to drinking half a bottle of wine daily. Calcium is 2.15 mmol/L, and arterial blood gas shows pH 7.38, pO2 11.2 kPa, pCO2 4.8 kPa. What is her predicted severity of acute pancreatitis according to the Glasgow score at 48 hours?

A. Score of 2 indicating moderately severe pancreatitis
B. Cannot be calculated without 48-hour blood results (Correct Answer)
C. Score of 1 indicating mild pancreatitis
D. Score of 3 or more indicating severe pancreatitis with high mortality risk
E. Score of 0 indicating no risk factors for severe disease

Explanation: ***Cannot be calculated without 48-hour blood results*** - The **Glasgow (Imrie) score** is specifically designed to be calculated and validated based on clinical and laboratory parameters at **48 hours after admission**. - Several required components (the **PANCREAS** mnemonic), such as **White Cell Count**, **Urea**, **LDH/AST**, **Albumin**, and **Glucose**, are missing from the current clinical vignette, making a formal score impossible to determine. *Score of 2 indicating moderately severe pancreatitis* - A score of 2 would imply **mild pancreatitis** under the Glasgow criteria; the term "moderately severe" is typically part of the **Atlanta Classification**, which is based on organ failure and complications rather than this point system. - Even if using Atlanta criteria, her **CRP of 180 mg/L** suggests high inflammatory activity, but her current **pO2 (11.2 kPa)** and calcium do not yet fulfill Glasgow criteria markers. *Score of 1 indicating mild pancreatitis* - While the patient’s pO2 and Calcium are currently within the "normal" range for the score, you cannot assign a final score of 1 until all **eight variables** are assessed at the 48-hour mark. - Early presentation findings can change rapidly; therefore, a score calculated before **48 hours** is considered unreliable for prognosis. *Score of 3 or more indicating severe pancreatitis with high mortality risk* - A score of **3 or more** signifies **severe acute pancreatitis**, but this patient currently only meets the CRP threshold (>150), which is not an official component of the Glasgow score. - Factors like her **Age (45)** and **pO2 (11.2 kPa)** currently do not count toward a high score, making a prediction of ">=3" premature. *Score of 0 indicating no risk factors for severe disease* - It is incorrect to assume a score of 0 simply because some values (like **Calcium 2.15 mmol/L**) are currently normal; other metrics like **Urea** or **LDH** are unknown. - The elevated **CRP (180 mg/L)** is a known independent predictor of severity, contradicting the idea that there are "no risk factors" present.

Question 37: A 65-year-old man with alcoholic cirrhosis and refractory ascites undergoes transjugular intrahepatic portosystemic shunt (TIPS) insertion. Before the procedure, his Model for End-Stage Liver Disease (MELD) score is 16, and his serum bilirubin is 42 μmol/L. Two weeks post-procedure, he develops progressive confusion and disorientation. His ascites has improved significantly. Liver function shows bilirubin 48 μmol/L, albumin 29 g/L, and INR 1.9. Ammonia level is elevated at 95 μmol/L (normal 11-35). What is the most likely complication?

A. TIPS stenosis leading to recurrent portal hypertension
B. Spontaneous bacterial peritonitis causing altered mental status
C. Post-TIPS hepatic encephalopathy due to increased portosystemic shunting (Correct Answer)
D. Progression of underlying liver disease with hepatic decompensation
E. Sepsis secondary to TIPS insertion

Explanation: ***Post-TIPS hepatic encephalopathy due to increased portosystemic shunting*** - **Hepatic encephalopathy** is the most frequent complication of **TIPS**, occurring because the shunt allows gut-derived toxins like **ammonia** to bypass hepatic metabolism and enter the systemic circulation. - The diagnosis is confirmed by the combination of new onset **confusion and disorientation**, **improved ascites** (indicating a patent shunt), and markedly **elevated ammonia levels** two weeks after the procedure. *TIPS stenosis leading to recurrent portal hypertension* - **TIPS stenosis** would typically lead to a recurrence or worsening of **portal hypertension** symptoms, most notably **recurrent ascites** or variceal bleeding, rather than improvement. - In this case, the patient's ascites has **significantly improved**, which indicates that the shunt is patent and functioning properly. *Spontaneous bacterial peritonitis causing altered mental status* - While **SBP** can trigger encephalopathy, it typically presents with signs of infection such as **fever**, abdominal pain, and often **worsening ascites** or new onset ascites. - There is no clinical evidence of infection (like fever or abdominal pain) or worsening ascites provided, making **SBP** less likely. *Progression of underlying liver disease with hepatic decompensation* - Progression of **underlying liver disease** leading to decompensation would be characterized by a significant worsening of **liver function tests**, such as a substantial increase in **bilirubin** and **INR**, and a decrease in **albumin**. - The patient's bilirubin, albumin, and INR levels are relatively stable post-TIPS, suggesting that overall liver synthetic function has not acutely deteriorated significantly. *Sepsis secondary to TIPS insertion* - **Sepsis** related to the procedure (e.g., from an infected shunt) would typically present with systemic signs of infection such as **fever**, **tachycardia**, and hemodynamic instability. - The isolated finding of new-onset **confusion** and **hyperammonemia** without systemic signs of infection strongly points toward **metabolic encephalopathy** rather than sepsis.

Question 38: A 29-year-old woman presents with a 2-year history of burning epigastric pain and acid regurgitation occurring 3-4 times per week, particularly at night. She has tried lifestyle modifications without improvement. BMI is 23 kg/m². Helicobacter pylori stool antigen test is negative. She is otherwise well and takes no regular medications. What is the most appropriate initial pharmacological management?

A. Prescribe ranitidine 300 mg at night for 4 weeks
B. Prescribe alginate therapy to be taken after meals and at bedtime
C. Prescribe a prokinetic agent such as metoclopramide
D. Prescribe a standard-dose proton pump inhibitor for 4-8 weeks (Correct Answer)
E. Arrange urgent upper GI endoscopy before starting treatment

Explanation: ***Prescribe a standard-dose proton pump inhibitor for 4-8 weeks*** - This patient presents with classic **Gastro-oesophageal reflux disease (GORD)** symptoms (burning epigric pain, acid regurgitation) occurring frequently, for which **Proton Pump Inhibitors (PPIs)** are the first-line and most effective treatment. - Given the patient is under 55 and lacks **alarm symptoms** (e.g., dysphagia, weight loss, anemia), an empirical trial of a full-dose PPI for 4 to 8 weeks is the most appropriate initial management. *Prescribe ranitidine 300 mg at night for 4 weeks* - **H2-receptor antagonists** like ranitidine are generally less effective than PPIs for healing oesophagitis and achieving complete symptom relief in moderate to severe GORD. - Furthermore, **ranitidine** has been largely withdrawn from the market due to concerns regarding **NDMA contamination**, making it an unsuitable choice. *Prescribe alginate therapy to be taken after meals and at bedtime* - While **alginates** can provide some symptomatic relief by forming a physical barrier, they are typically less effective for the frequent and persistent symptoms described, often reserved for **mild or infrequent reflux**. - These agents are usually considered adjunct therapy or for on-demand use, not as the primary initial pharmacological management for significant GORD. *Prescribe a prokinetic agent such as metoclopramide* - **Prokinetic agents** have a very limited role and are not recommended as first-line therapy for GORD due to inconsistent efficacy in reducing acid reflux. - **Metoclopramide** specifically carries a significant risk of **neurological side effects**, including extrapyramidal symptoms, which outweighs its potential benefit in GORD. *Arrange urgent upper GI endoscopy before starting treatment* - **Upper GI endoscopy** is not indicated as initial management in this patient because she is young (<55 years old) and does not present with any **alarm features** such as dysphagia, unintentional weight loss, anemia, or persistent vomiting. - For typical GORD symptoms in younger patients without alarm features, an **empirical trial of PPI therapy** is the recommended first step before considering endoscopy.

Question 39: A 54-year-old man with alcoholic cirrhosis and large oesophageal varices on recent endoscopy is commenced on prophylactic carvedilol. After 4 weeks, his resting heart rate has decreased from 82 bpm to 58 bpm. He reports mild fatigue but no dizziness or syncope. Blood pressure is 108/68 mmHg. Liver function tests show bilirubin 38 μmol/L, albumin 32 g/L, and INR 1.6. What is the most appropriate management of his carvedilol therapy?

A. Continue current dose as the heart rate reduction indicates adequate beta-blockade (Correct Answer)
B. Stop carvedilol and arrange repeat endoscopy for variceal banding
C. Switch from carvedilol to propranolol for better tolerability
D. Reduce the carvedilol dose as heart rate is below the target range
E. Increase the carvedilol dose to achieve greater portal pressure reduction

Explanation: ***Continue current dose as the heart rate reduction indicates adequate beta-blockade*** - The goal for **non-selective beta-blockers (NSBB)** in portal hypertension is a heart rate (HR) reduction to roughly **55–60 bpm** or a 25% decrease from baseline; this patient’s HR of **58 bpm** indicates therapeutic success. - Since the patient is **hemodynamically stable** (BP 108/68 mmHg) and lacks signs of hypoperfusion like **syncope or dizziness**, the mild fatigue is an expected side effect that does not mandate discontinuation. *Stop carvedilol and arrange repeat endoscopy for variceal banding* - **Endoscopic Variceal Ligation (EVL)** is an alternative for primary prophylaxis, but there is no clinical indication to switch when the current medical therapy is **effective and well-tolerated**. - Stopping a successful NSBB regimen without a contraindication (like **refractory ascites or hypotension**) unnecessarily increases the risk of **variceal hemorrhage**. *Switch from carvedilol to propranolol for better tolerability* - **Carvedilol** is generally more effective than **propranolol** for reducing portal pressure because it also possesses **alpha-1 adrenergic blocking** properties. - Switching is unnecessary as the patient has already achieved the target HR and is not exhibiting a significant **intolerance** that would be solved by a different NSBB. *Reduce the carvedilol dose as heart rate is below the target range* - The heart rate of **58 bpm** is exactly within the recommended target range of **55–60 bpm**, not below it. - Reducing the dose would likely push the heart rate back up and potentially lose the **protective benefit** against variceal bleeding. *Increase the carvedilol dose to achieve greater portal pressure reduction* - Increasing the dose further would likely result in **symptomatic bradycardia** or significant **hypotension**, especially since the heart rate is already at the lower therapeutic bound. - Unlike propranolol, **Carvedilol** is typically administered at fixed low doses (e.g., 6.25–12.5 mg) rather than being titrated solely by HR, and further escalation is limited by **systemic blood pressure**.

Question 40: A 33-year-old man presents with a 4-week history of intermittent lower abdominal cramping and loose stools occurring 3-4 times daily. He reports that symptoms worsen with stress and improve after bowel movements. There is no blood in the stools, no nocturnal symptoms, and no weight loss. Examination is unremarkable. Blood tests including full blood count, inflammatory markers, coeliac serology, and thyroid function are all normal. Faecal calprotectin is 18 μg/g (normal <50 μg/g). What is the most appropriate next step?

A. Arrange colonoscopy to exclude inflammatory bowel disease
B. Request CT abdomen and pelvis to exclude colonic malignancy
C. Arrange hydrogen breath testing to exclude small intestinal bacterial overgrowth
D. Diagnose irritable bowel syndrome and provide dietary advice and reassurance (Correct Answer)
E. Prescribe a trial of mesalazine for possible microscopic colitis

Explanation: ***Diagnose irritable bowel syndrome and provide dietary advice and reassurance***- This patient's symptoms (abdominal pain related to defecation, altered bowel habits, worsening with stress) combined with the absence of **alarm features** (no blood, no nocturnal symptoms, no weight loss) and normal investigations (FBC, inflammatory markers, coeliac serology, thyroid, and crucially, normal **faecal calprotectin**) are highly characteristic of **Irritable Bowel Syndrome (IBS)**.- Given the clinical picture and the thorough exclusion of organic pathology with normal **faecal calprotectin** (which rules out IBD with high negative predictive value), further invasive investigations are not warranted, and management should focus on **IBS diagnosis**, reassurance, and **dietary advice** (e.g., FODMAP diet).*Arrange colonoscopy to exclude inflammatory bowel disease*- A **normal faecal calprotectin** (<50 μg/g) has a high negative predictive value for **Inflammatory Bowel Disease (IBD)**, making a colonoscopy unnecessary in the absence of other red flags.- The patient lacks typical features of IBD such as **nocturnal diarrhea**, **rectal bleeding**, or **unexplained weight loss**, and **inflammatory markers** are normal.*Request CT abdomen and pelvis to exclude colonic malignancy*- Colonic malignancy is highly unlikely in a 33-year-old man without any **alarm features** (e.g., weight loss, rectal bleeding, iron deficiency anemia, family history of early-onset colorectal cancer).- Performing a CT scan would expose the patient to unnecessary **ionizing radiation** when the clinical picture strongly points towards a functional gastrointestinal disorder.*Arrange hydrogen breath testing to exclude small intestinal bacterial overgrowth*- While **SIBO** can cause symptoms like bloating and altered bowel habits, it is not typically the initial investigation when the clinical presentation strongly aligns with **IBS** and other organic causes have been ruled out.- **Hydrogen breath testing** for SIBO is usually considered in patients with persistent symptoms despite initial IBS management or those with specific risk factors for SIBO (e.g., prior bowel surgery, diverticulosis).*Prescribe a trial of mesalazine for possible microscopic colitis*- **Microscopic colitis** typically presents with chronic, watery diarrhea, often without abdominal pain, and predominantly affects **older patients**.- Diagnosis requires **colonic biopsies** (usually during colonoscopy), and **mesalazine** is not the primary treatment (budesonide is preferred). The patient's symptoms and age do not strongly suggest microscopic colitis.

Practice by Chapter

Acute pancreatitis

Practice Questions

Cirrhosis and complications

Practice Questions

Dyspepsia and GORD

Practice Questions

Inflammatory bowel disease

Practice Questions

Irritable bowel syndrome

Practice Questions

Upper GI bleeding

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free